Skip to main content
Clinical Trials/IRCT138711051556N1
IRCT138711051556N1
Completed
Phase 2

Saffron extract in the treatment of mild to moderate Alzheimer’s disease: A double blind randomized controlled trial.

Tehran University of Medical Sciences0 sites50 target enrollmentTBD

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Not specified
Sponsor
Tehran University of Medical Sciences
Enrollment
50
Status
Completed
Last Updated
8 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
8 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Inclusion Criteria:
  • A diagnosis of probable Alzheimer’s disease according to the criteria of National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer’s Disease and Related Disorders Association (NINCDS/ADRDA); Presence of mild to moderate dementia \[score of \= 12 on the cognitive subscale of Alzheimer’s Disease Assessment Scale (ADAS\-cog) and \= 2 on Clinical Dementia Rating Scale (CDR)].

Exclusion Criteria

  • Concomitant diseases such as hypertension, congestive heart failure, non\-insulin dependent diabetes mellitus and hypothyroidism; Patients with evidence of other neurodegenerative disorders; Any cardiovascular disease likely to prevent completion of the study; Clinically significant psychiatric diseases; Urinary outflow obstruction; Active peptic ulcer; Any history of epilepsy; Significant drug or alcohol misuse; Drugs with anticholinergic effects or cholinomimetic effects.

Outcomes

Primary Outcomes

Not specified

Similar Trials